Co-Diagnostics CODX · Analysis & News
- Co-Diagnostics has moved its third quarter 2026 earnings release up to November 10 after market close, two days earlier than planned.
- There is no fresh business or financial news to weigh, and no technical signal picture, so the overall reading stays neutral.
- The earnings call and webcast follow the release on November 10 at 4:30 p.m. ET; the results, not the schedule change, are what can move the stock.
- Heavy US economic data lands within days, including payrolls today and inflation figures in four days, shaping the broader market backdrop.
News situation · 2 items / 30 D
2 of 2 straight from the issuer or regulator
Outlook for Co-Diagnostics
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- Q3 2026 earnings release on November 10, 2026, after market close, moved up two days from the original date
- Conference call and webcast on November 10, 2026, at 4:30 p.m. ET, where management commentary may add colour beyond the numbers
What argues against it
- The earnings results themselves are the main unknown; until November 10 there is little fresh company information to work from
- The US employment report lands within a day and inflation data follows in four days; surprises there can swing overall market sentiment and hit smaller stocks hardest
- With no chart signals and only scheduling news on file, a single unexpected announcement could quickly change the picture in either direction
Coming up
- US: Consumer prices · expected 2.8%, previous 2.6%
- US: Jobless claims
Economic data for CODX
Full calendarRecently released
- November 6, 2026USDMichigan Consumer Sentiment●●●Forecast 48.5Previous 48.0
- November 6, 2026USDUnemployment Rate●●●Forecast 4.2%Previous 4.2%
- November 6, 2026USDAverage Hourly Earnings m/m●●●Forecast 0.2%Previous 0.1%
- November 6, 2026USDNonfarm Payrolls●●●Forecast 55KPrevious 29K
- November 5, 2026USDInitial Jobless Claims●●●
Coming up
- November 10, 2026USDCore CPI y/y●●●Forecast 2.8%Previous 2.6%in 2 days
- November 10, 2026USDCPI y/y●●●Forecast 4.2%Previous 3.7%in 2 days
- November 10, 2026USDCore CPI m/m●●●Forecast 0.2%Previous 0.3%in 2 days
- November 10, 2026USDCPI●●●Forecast 338.683Previous 336.298in 2 days
- November 10, 2026USDCPI m/m●●●Forecast 0.5%Previous 0.6%in 2 days
- November 10, 2026USDCore CPI n.s.a. m/m●●●Previous 0.4%in 2 days
- November 10, 2026USDCore CPI●●●Forecast 339.796Previous 338.896in 2 days
- November 12, 2026USDInitial Jobless Claims●●●in 4 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about CODX
In-depth analysis of Co-Diagnostics
AI-generated · as of November 5, 2026
Co-Diagnostics enters the week with a quiet news flow and no directional push in either direction. The one concrete development is scheduling: the company has pulled its third quarter 2026 earnings release forward to Tuesday, November 10, after market close, from November 12, with the conference call and webcast following at 4:30 p.m. ET the same evening.
Read full analysis
A scheduling change carries no financial figures, no guidance and no business update, so it does not alter the company's fundamentals; any price effect will come from the results themselves on the new date. Beyond that, the picture is thin. There is no current signal picture from the charts, and the recent news items are both routine scheduling announcements, one from today and one from a week ago, neither with a positive or negative slant. That leaves the stock without a clear bull or bear case from either side, which is why the overall reading is neutral rather than leaning anywhere. The wider market backdrop is busy: weekly jobless claims and the ISM services readings are already behind us, while the US employment report is due within a day and consumer inflation figures follow in four days. Those releases set the general tone for risk appetite in smaller stocks, but they carry no fixed direction for Co-Diagnostics specifically. What can change this neutral stance is straightforward: the Q3 results and call on November 10, and any company announcement between now and then.
Frequently asked questions about Co-Diagnostics
When does Co-Diagnostics report its third quarter results?
The company moved the release up to Tuesday, November 10, 2026, after market close, two days earlier than the previously announced November 12. The conference call and webcast take place the same evening at 4:30 p.m. ET. Because the date change involves no figures or guidance, it is the results on the new date that matter for the stock, not the scheduling itself.
Why is the overall view neutral when earnings are just days away?
Neutrality here reflects a genuine lack of directional evidence, not a hidden opinion. The only recent news is the earnings scheduling change, which is neither good nor bad, and there is no technical signal picture to lean on either. Before the numbers land, there is simply nothing in the available information that argues convincingly for the share price to move up or down.
What should I watch around the November 10 earnings date?
Three things. First, the results themselves after the close on November 10 and what management says on the 4:30 p.m. ET call. Second, the broader market reaction to the US employment report due within a day and the inflation figures following about four days later, which can set the tone for smaller stocks regardless of company news. Third, any interim company announcement between now and the release, which would be the first substantive update in the current news flow.
Do the upcoming US economic reports affect this stock?
Only as background. The employment and inflation releases shape overall risk appetite and rate expectations, and smaller company shares often feel market-wide swings more than large caps do. But none of these releases has a fixed directional link to Co-Diagnostics itself. They can amplify or dampen how the stock trades around earnings, yet they do not say anything about the company's own results or prospects.
📝 Overview Generated automatically
CODX has been the subject of 2 signals across 2 articles in the last 365 days. Sentiment skews Neutral (100%).
Breakdown: 0 bullish, 0 bearish, 2 neutral.
Most-cited catalysts: Q3 2026 earnings release on November 10, 2026, after market close, two days earlier than planned (1×), Conference call and webcast on November 10, 2026, at 4:30 p.m. ET (1×).